Injectable migraine treatment approved

But there’s a catch: it’s expensive

The first in a new class of drugs for preventing migraine, the long-acting injectable medication erenumab has been approved for use in Australia.

Erenumab has been registered by the TGA as a treatment targeting the calcitonin gene-related peptide (CGRP) receptor for migraine prophylaxis in adults.